NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Register
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Studies presented at the ESMO Gastrointestinal Cancers Congress 2024 could improve outcomes through better patient selection...
Neoadjuvant immunotherapy given for stage III melanoma, followed by adjuvant therapy only if there is not...
Osimertinib improves PFS in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC)...
The antibody-drug conjugate trastuzumab deruxtecan delays cancer growth for women with hormone receptor-positive (HR+)...
According to a new study presented at the 2024 ASCO Annual Meeting, adding the antibody-drug conjugate...
For patients with locally advanced oesophageal adenocarcinoma that can be treated with surgery, chemotherapy treatment...
The management of bladder cancer is evolving rapidly, with a new regimen recently approved for patients...
Review aims to implement a more personalised and multidisciplinary approach in treatment of menopause...
The Congressional Caucus heard how a unique partnership has significantly increased both the quality and...
Michelle, a 46-year-old female, underwent biopsy of a lesion in her left sided chest musculature in...
In this issue, highlights from the 2023 Gathering Around Cancer as well as national and international...
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT